Protein Engineering, Vol. 12, No. 10, 873-878,
October 1999
© 1999 Oxford University Press
Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling
Department of Biotechnology, Royal Institute of Technology (KTH), S-100 44 Stockholm, Sweden
The possibility of increasing the affinity of a Taq DNA polymerase specific binding protein (affibody) was investigated by an 
-helix shuffling strategy. The primary affibody was from a naive combinatorial library of the three-helix bundle Z domain derived from staphylococcal protein A. A hierarchical library was constructed through selective re-randomization of six amino acid positions in one of the two -helices of the domain, making up the Taq DNA polymerase binding surface. After selections using monovalent phage display technology, second generation variants were identified having affinities (KD) for Taq DNA polymerase in the range of 30–50 nM as determined by biosensor technology. Analysis of binding data indicated that the increases in affinity were predominantly due to decreased dissociation rate kinetics. Interestingly, the affinities observed for the second generation Taq DNA polymerase specific affibodies are of similar strength as the affinity between the original protein A domain and the Fc domain of human immunoglobulin G. Further, the possibilities of increasing the apparent affinity through multimerization of affibodies was demonstrated for a dimeric version of one of the second generation affibodies, constructed by head-to-tail gene fusion. As compared with its monomeric counterpart, the binding to sensor chip immobilized Taq DNA polymerase was characterized by a threefold higher apparent affinity, due to slower off-rate kinetics. The results show that the binding specificity of the protein A domain can be re-directed to an entirely different target, without loss of binding strength.
Keywords: affibody/affinity maturation/phage display/staphylococcal protein A/Taq DNA polymerase
1 To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Tolmachev, M. Friedman, M. Sandstrom, T. L.J. Eriksson, D. Rosik, M. Hodik, S. Stahl, F. Y. Frejd, and A. Orlova Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry J. Nucl. Med., February 1, 2009; 50(2): 274 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Friedman, E. Nordberg, I. Hoiden-Guthenberg, H. Brismar, G.P. Adams, F.Y. Nilsson, J. Carlsson, and S. Stahl Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor Protein Eng. Des. Sel., April 23, 2007; (2007) gzm011v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rothe, R. J. Hosse, and B. E. Power In vitro display technologies reveal novel biopharmaceutics FASEB J, August 1, 2006; 20(10): 1599 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tolmachev, F. Y. Nilsson, C. Widstrom, K. Andersson, D. Rosik, L. Gedda, A. Wennborg, and A. Orlova 111In-Benzyl-DTPA-ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors J. Nucl. Med., May 1, 2006; 47(5): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Orlova, M. Magnusson, T. L.J. Eriksson, M. Nilsson, B. Larsson, I. Hoiden-Guthenberg, C. Widstrom, J. Carlsson, V. Tolmachev, S. Stahl, et al. Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. Cancer Res., April 15, 2006; 66(8): 4339 - 4348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wikman, A.-C. Steffen, E. Gunneriusson, V. Tolmachev, G.P. Adams, J. Carlsson, and S. Stahl Selection and characterization of HER2/neu-binding affibody ligands Protein Eng. Des. Sel., May 1, 2004; 17(5): 455 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wernerus, P. Samuelson, and S. Stahl Fluorescence-Activated Cell Sorting of Specific Affibody-Displaying Staphylococci Appl. Envir. Microbiol., September 1, 2003; 69(9): 5328 - 5335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. K. Deng, L. A. Nesbit, and K. J. Morrow Jr. Recombinant Single-Chain Variable Fragment Antibodies Directed against Clostridium difficile Toxin B Produced by Use of an Optimized Phage Display System Clin. Vaccine Immunol., July 1, 2003; 10(4): 587 - 595. [Abstract] [Full Text] [PDF]
|
|